drugset
drugset / Trial / NCT07336797

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

NCT07336797 ↗

Phase 2 Recruiting 66 enrolled Abdelrahman Mahmoud
RandomizedParallel-groupTriple-blindTreatment

Summary

We investigate the role of empagliflozin in the treatment of obesity in PLWH.

Timeline

Start
2025-09-01
Primary completion
2026-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg Oral

Indications

HIV infectious disease metabolic syndrome X obesity disorder